Quick Answer
NOVAVAX INC reported Cash and Equivalents of $240.63 million for fiscal year 2025.
NOVAVAX INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $240.63M | -54.6% |
| 2024 | $530.23M | -6.7% |
| 2023 | $568.50M | -57.5% |
| 2022 | $1.34B | -11.8% |
| 2021 | $1.52B | +173.8% |
| 2020 | $553.40M | +602.1% |
| 2019 | $78.82M | +12.4% |
| 2018 | $70.15M | -34.0% |
| 2017 | $106.31M | -26.4% |
| 2016 | $144.35M | +55.0% |
| 2015 | $93.11M | +187.9% |
| 2014 | $32.34M | -72.9% |
| 2013 | $119.47M | +586.7% |
| 2012 | $17.40M | +23.4% |
| 2011 | $14.10M | +75.0% |
| 2010 | $8.06M | -79.2% |
| 2009 | $38.76M | +43.9% |
| 2008 | $26.94M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $268.02M | -53.3% | +5.6% |
| June 30, 2025 | $253.74M | -62.7% | -3.6% |
| March 31, 2025 | $263.34M | -45.2% | -50.3% |
| December 31, 2024 | $530.23M | -6.7% | -7.6% |
| September 30, 2024 | $573.63M | -11.9% | -15.7% |
| June 30, 2024 | $680.16M | +34.4% | +41.5% |
| March 31, 2024 | $480.59M | -23.1% | -15.5% |
| December 31, 2023 | $568.50M | -57.5% | -12.7% |
- NOVAVAX INC showed a decrease of -54.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, NOVAVAX INC’s cash and equivalents has grown by 793.3% (from $26.94 million to $240.63 million).
- The most recent figure is from NOVAVAX INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: